<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854227</url>
  </required_header>
  <id_info>
    <org_study_id>C3851001</org_study_id>
    <nct_id>NCT03854227</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study Of PFâ€‘06939999 In Participants With Advanced Or Metastatic Solid Tumors</brief_title>
  <official_title>A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06939999 (PRMT5 INHIBITOR) IN PARTICIPANTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, HEAD AND NECK SQUAMOUS CELL CARCINOMA, ESOPHAGEAL CANCER, ENDOMETRIAL CANCER, CERVICAL CANCER AND BLADDER CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open label, multi center, dose escalation and expansion, safety,
      tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients
      with advanced or metastatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2019</start_date>
  <completion_date type="Anticipated">July 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 27, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dose Escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>Baseline through day 28</time_frame>
    <description>DLTs will be evaluated during the first cycle. The number of DLTs will be used to determine the maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment emergent adverse events (AEs)</measure>
    <time_frame>Baseline through approximately 2 years</time_frame>
    <description>Adverse events as characterized by type, frequency, severity, timing, seriousness and relationship to study therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with laboratory abnormalities</measure>
    <time_frame>Baseline through approximately 2 years</time_frame>
    <description>Laboratory abnormalities as characterized by type, frequency, severity, and timing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including Maximum Observed Plasma Concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including Time to reach Maximum Observed Plasma Concentration (Tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Area Under the Curve from time 0 to the last sampling time point within the dose interval (AUClast)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including Area Under the Curve from time 0 to the last sampling time point within the dose interval (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Terminal elimination half life (t1/2)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including, as data permit, terminal elimination half life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: AUC from time 0 extrapolated to infinity (AUCinf)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including, as data permit, Area Under the Curve from time 0 extrapolated to infinity (AUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Apparent oral plasma clearance (CL/F)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including, as data permit, apparent oral plasma clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including, as data permit, apparent volume of distribution (Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Maximum Observed Steady State Plasma Concentration (Css,max)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Multiple dose PK will be calculated including Maximum Observed Steady State Plasma Concentration (Css,max).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Time to reach Maximum Observed Steady State Plasma Concentration (Tss,max)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Multiple dose PK will be calculated including Time to reach Maximum Observed Steady State Plasma Concentration (Tss,max).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Area Under the Curve within one dose interval (AUCss,t)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Multiple dose PK will be calculated including Area Under the Curve within one dose interval (AUCss,t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Steady state apparent oral plasma clearance (CL/F)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8. 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Multiple dose PK will be calculated including, as data permit, steady state apparent oral plasma clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Steady state apparent volume of distribution (Vss/F)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Multiple dose PK will be calculated including, as data permit, steady state apparent volume of distribution (Vss/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Accumulation ratio (Rac)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Multiple dose PK will be calculated including, as data permit, accumulation ratio (Rac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Baseline through up to 24 months</time_frame>
    <description>Tumor response as assessed using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Baseline through up to 24 months</time_frame>
    <description>Duration of response as assessed using RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 at 0.5 mg once a day (QD) in 28 day cycles on a continuous basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 at 0.5 mg BID in 28 day cycles on a continuous basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 at 1 mg twice a day (BID) in 28 day cycles on a continuous basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 at 2 mg BID in 28 day cycles on a continuous basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 at 4 mg BID in 28 day cycles on a continuous basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 at 8 mg BID in 28 day cycles on a continuous basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 at &lt;=32 mg total daily dose (QD or BID) in 28 day cycles on a continuous basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level to be determined (TBD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 at a dose TBD (QD or BID) in 28 day cycles on a continuous basis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06939999</intervention_name>
    <description>0.5 mg QD orally on a continuous basis</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <other_name>PRMT5 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06939999</intervention_name>
    <description>0.5 mg BID orally on a continuous basis</description>
    <arm_group_label>Dose Level 2</arm_group_label>
    <other_name>PRMT5 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06939999</intervention_name>
    <description>1 mg BID orally on a continuous basis</description>
    <arm_group_label>Dose Level 3</arm_group_label>
    <other_name>PRMT5 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06939999</intervention_name>
    <description>2 mg BID orally on a continuous basis</description>
    <arm_group_label>Dose Level 4</arm_group_label>
    <other_name>PRMT5 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06939999</intervention_name>
    <description>4 mg BID orally on a continuous basis</description>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>PRMT5 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06939999</intervention_name>
    <description>8 mg BID orally on a continuous basis</description>
    <arm_group_label>Dose Level 6</arm_group_label>
    <other_name>PRMT5 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06939999</intervention_name>
    <description>&lt;=32 mg (QD or BID) orally on a continuous basis</description>
    <arm_group_label>Dose Level 7</arm_group_label>
    <other_name>PRMT5 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06939999</intervention_name>
    <description>Dose TBD (QD or BID) orally on a continuous basis</description>
    <arm_group_label>Dose Level to be determined (TBD)</arm_group_label>
    <other_name>PRMT5 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who are intolerant or resistant to standard treatment for selected solid
             tumors

          -  At least one measurable lesion as defined by RECIST version 1.1

          -  ECOG Performance Status 0 or 1

          -  Adequate Bone Marrow Function

          -  Adequate Renal Function

          -  Adequate Liver Function

          -  Resolved acute effects of any prior therapy

        Exclusion Criteria:

          -  Known active uncontrolled or symptomatic CNS metastases.

          -  Major surgery, radiation therapy, systemic anti-cancer therapy or investigational
             drug(s) within 4 weeks prior to study entry.

          -  Active, uncontrolled infection

          -  Known or suspected hypersensitivity to PF-06939999

          -  Inability to consume or absorb study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scottsdale Healthcare Hospitals d/b/a HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Pharmacy</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry-Joyce Cancer Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology IDS Pharmacy</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute Infusion Pharmacy</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3851001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

